Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and enterococci by FIC index and timed-kill curves

Journal of Chemotherapy

Volumn 17, Issue 6, 2005, Pages 614-621

  Snydman, David R ^a   Mcdermott, L A ^a   Jacobus, N V ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Antagonism; Bactericidal effect; Checkerboard methods; Daptomycin; Synergy; Time kill curves

Indexed keywords

AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTRIAXONE; DAPTOMYCIN; GENTAMICIN; IMIPENEM; OXACILLIN;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CONCENTRATION; DRUG POTENTIATION; ENTEROCOCCUS; FIC INDEX; FRACTIONAL INHIBITORY CONCENTRATION INDEX; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; TIMED KILL CURVE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN SUSCEPTIBLE ENTEROCOCCUS FAECALIS;

EID: 30744452985     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.6.614     Document Type: Article

References (18)

1. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999;20(2):303-315.
2. Barry AL, Fuchs PC, Brown S. In vitro activity of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1919-1922.
3. Jones RN, Barry AL. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother 1991;31:625-29.
4. King A, Phillips I. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother 2001;48:219-223.
5. Rybak MJ, Hershberger E, Moldovan T, Grutz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000;44:1062-1066.
6. Silva M, Jacobus NV, Gorbach SL. In vitro activity of LY146032 against Gram-positive bacteria. Diag Microbiol Infect Dis 1988;9:79-85.
7. Snydman DR, Jacobus NV, McDermott LA et al. Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob Agents Chemother 2000;44:3447-3450.
8. Tally FP, Zeckel M, Wasilewski MG, et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investigat Drugs. 1999;8(8):1223-1238.
9. Thorne GM, Adler J. Daptomycin: A novel lipopeptide antibiotic. Clin Microbiol Newslett 2002;24(5):33-39.
10. Wise R, Andrews JM, Ashby JP. The activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001;48:563-567.
11. th ed. NCCLS 2000 Wayne, PA, USA.
12. National Committee for Clinical Laboratory Standards (renamed National Institute for Clinical Laboratory Standards, 2005). Methods for determining bactericidal activity of antimicrobial agents. M26-T, vol. 12, no. 19. NCCLS 1992. Wayne, PA, USA.
13. Odds FC. Synergy, antagonism, and what the checker-board puts between them. [Editorial] J Antimicrob Agents Chemother 2003;52:1.
14. th ed. pp330-396. Baltimore, Maryland:Williams and Wilkins, 1996.
15. Leclercq R, Bingen E, Su QH, Lambert-Zechovski N, Courvalin P, Duval J. Effects of combinations of β-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 1991;35:92-98.
16. Bingen E, Lambert-Zechovski N., Leclercq R, Doit C, Mariani-Kurkdjian P. Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1990;26:619-26.
17. Louie A, Baltch AL, Ritz WJ, Smith RP, Asperilla M. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 145032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. Chemotherapy 1993;39:302-310.
18. Atkins RL, Rybak MJ. In vitro activities of daptomycin, arbekacin, vancomycin and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 2000;44:1925-1929.